Long-term clinical trials in Japan and The Netherlands demonstrate that interferon nonresponder patients with chronic hepatitis C and fibrosis stage 3 or 4 have a reduced incidence rate of HCC after glycyrrhizin therapy normalizes ALT levels [105, 106] . Other well-diagnosed studies are needed to better define the role of GL in HBV and HCVrelated liver disease.